We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » GDUFA II to Review 90 Percent of Priority Submissions in 8 Months

GDUFA II to Review 90 Percent of Priority Submissions in 8 Months

November 18, 2016

The FDA intends to review 90 percent of priority review ANDAs deemed complete within 8 months, according to the agency’s GDUFA II commitment letter.

The full commitment letter, which was released late Friday, further explains the performance goals the FDA has committed to for the next five fiscal years after 2017, when the current agreement expires.

As in GDUFA I, the FDA plans to respond to regular ANDAs within 10 months after submission. In the past, the FDA faced a significant backlog of ANDAs that totaled more 4,700 applications. Only in the last few months has the agency reported acting on more than 90 percent of those items.

The FDA is, however, saying that it will aim to notify generics makers of its decision to receive or refuse an ANDA within 60 days of submission. Previously, under GDUFA I, the FDA had not made provisions for this.

The timeframe for the FDA to act on prior approval supplements remains the same as in the GDUFA I. In the GDUFA II letter, the FDA commits to responding to standard PASs that do not require a preapproval inspection within six months after submission. For those with preapproval inspections, the FDA pledges to act within 10 months of the submission date.

Additionally, the letter commits the FDA to responding to product development meeting requests within 30 days of the request for FY 2018 and 2019. For the last three years of the user fee goals, the FDA intends to quicken turnaround and respond within 90 days of receipt of the request. These would be entirely new provisions in GDUFA that were not addressed in the first user fee agreement.

Order your copy of Achieving ANDA Success: Working with the FDA to Win First-Cycle Approval today — applicants who get it right the first time can get their products to market quicker.

View today's stories

Pharmaceuticals Regulatory Affairs

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • WhiteHouse.gif

    President Biden Issues Executive Order on U.S. Supply Chain

  • roche.gif

    Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

  • Effective text

    Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

  • Siemens Healthineers logo

    Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing